Staple your payment here 請將股款 緊釘在此

This Application Form uses the same terms as defined in the prospectus of Sisram Medical Ltd (the "Company") dated September 5, 2017 (the "Prospectus").

本申請表格使用Sisram Medical Ltd (「本公司」)於二零一七年九月五日刊發的招股章程(「招股章程」)所界定的 相同詞語

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act. 本申請表格及招股章程概不構成在香港以外司法權區要約出售或游説要約購買香港發售股份。若無根據美國《證券法》登記或豁免登記,香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法權區內概不得發达或派發或複製(不 論方式,也不論全部或部分)本申請表格及招股章程。

Copies of the Prospectus, all related Application Forms and the other documents specified in the "Documents Delivered to the Registrar of Companies and Available for Inspection" section in Appendix VI to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by section 342°C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance. Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKS CC"), the Securities and Futures Commission of Hong Kong Companies in Hong Kong talk and securities and Futures Commission of Hong Kong Companies in Hong Kong talk and securities and Futures of Companies in Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures Commission of Hong Kong talk and securities and Futures and Futures Commission of Hong Kong talk and securities and Futures and Kong (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility for the contents of these documents. 招股章程、所有相關申請表格及招股章程附錄六[ 送呈公司註冊處處長及備查文件]一節所述其他文件已根據《公司(清盤及雜項條文)條例》第342C條規定送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。

# Sisram Medical Ltd

(Incorporated in Israel with limited liability) (於以色列註冊成立的有限公司)

> 1696 Stock code 股份代號 1696

HK\$1235 per Offer Share, plus brokerage of 1%, **Maximum Offer Price** 

> SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in

**Hong Kong dollars and subject to refund)** 

高發售價

每股發售股份12.35港元,另加1%經紀佣金、 0.0027% 證監會交易徵費及0.005% 聯交所交易 費(股款須於申請時以港元繳足,多繳股款可予

You should read this Application Form in conjunction with the Prospectus, which contains further information on the application procedures.

招股章程尚有關於申請程序的其他資料,本申請表格應與招股章程一併閱讀。

#### **Application Form** 申請表格

To: Sisram Medical Ltd Joint Sponsors Joint Global Coordinators Joint Bookrunners

The Hong Kong Underwriters

Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the "Effect of completing and submitting this Application Form" section of this Application Form.

Warning: Only one application may be made for the benefit of any person (other than an application (if any) made either through the Blue Form eIPO service via www.eipo.com.hk or on a BLUE Application Form in the capacity as a Qualifying Fosun International Shareholders). Please refer to the last four bullets of "Effect of completing and submitting this Application Form" section.

致: Sisram Medical Ltd 聯席保薦人 聯席全球協調人 聯席賬簿管理人 香港包銷商

## 申請人聲明

本人/吾等同意本申請表格及招股章程的條款及條件 以及申請程序。見本申請表格「填交本申請表格的效 用 一節。

警告:任何人士只限作出一次為其利益而進行的認購 申請(通過www.eipo.com.hk採用藍表eIPO服務或以 合資格復星國際股東身份採用藍色申請表格提出的申 請(如有)除外)。請參閱「填交本申請表格的效用 |--節最後四點。

Class J. Land (all) and Canada (a) (all tates and the control of t	1) 100 to 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1 = 1				
Signed by (all) applicant(s) (all joint applicants must sign): 由(所有)申請人簽署(所有聯名申請人必須簽署):	For Broker use 此欄供經紀填寫 Lodged by 遞交申請的經紀				
由 (2/14) 年 昭75來年 (2/16 78/4 年 昭75年) ·	(Broker No. 經紀號碼) Broker's Chop 經紀印章				
Date: 日期:  D日 M月 Y年  Number of Hong Kong Offer Shares applied for (not more than 5,500,000 shares)					
申請香港發售股份數目(不超過5,500,000 股股份)	Cheque/banker's cashier order number 支票/銀行本黑號碼				
Total amount 總額	Name of bank on which cheque/Banker's cash er order is drawn (see "How to make your application" section 兑現支票				
HK\$ 港元	/銀行本票的銀行名稱(見「申請手續」一節) 				
Name in English 英文姓名/名稱					
Family name or company name 姓氏或公司名稱	Forename(s) 名字				
Name in Chinese 中文姓名/名稱					
Family name or company name 姓氏或公司名稱	Forename(s) 名字				
Occupation in English 職業(以英文填寫)	Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No.* (Please delete as appropriate) 香港身份證號碼/護照號碼/香港商業登記號碼*(請刪除不適用者)				
Names of all other joint applicants in English (if any) 所有其他聯名申請人的英文姓名/名稱(如有)	Hong Kong Identity Card No./Passport No./Hong Kong Business Reg.stration No. of all other joint applicants* (Please delete as appropriate) 所有其他聯名申請人的香港身份證號碼/護照號碼/香港商業登記號碼*(請刪除不適用者)				
2)	1)				
2)	2)				
3)	3)				
Hong Kong address in English and telephone no. (joint applicants applicant only)香港地址(以英文填寫)和電話號碼(聯名申請人只	should give the address and the telephone number of first named只須填寫排名首位申請人的地址及電話號碼)				
	T				
For Nominees: You will be treated as applying for your own	Telephone No. 電話號碼				
benefit if you do not complete this section. Please provide an	THIS BOX MUST BE DULY COMPLETED 必須填妥此欄				
account number or identification code for each (joint) beneficial owner. 由代名人遞交:代名人若不填寫本節,是項認購申請將視作為 閣下利益提出。請填寫每名(聯名)實益擁有人的賬戶號碼或識別編碼	Participant I.D. of the CCASS Investor Participant or designated CCASS Participant 中央結算系統投資者戶口持有人或指定的中央結算系統參與者的參與者編號				
ADDRESS LABEL 地址標貼 (Your name(s) and address in Hong Kong in BLOCK letters 請用英文正楷填寫姓名/名稱及香港地址)	For designated CCASS Participant or Corporate CCASS Investor Participant, please also affix the company chop bearing its company name 指定的中央結算系統參與者或中央結算系統公司投資者戶口持有人,請加蓋顯示公司名稱的公司印鑑				
For Internal use 此欄供內部使用	(See paragraph 2 in the section "How to make your application") (請參閱「申請手續」一節第2段)				

- \* (1) If you are a CCASS Investor Participant, only a Hong Kong Identity Card number (if you are an individual) or a Hong Kong Business Registration number (if you are a body corporate) will be accepted for this application, please see paragraph 2 under the section "How to make your application". 如 閣下為中央結算系統投資者戶口持有人,是項申請僅接納香港身份證號碼(如屬個別人士)或香港商業登記號碼(如屬法人團體);請參閱「申請手續」一節第2段。
  - (2) If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For an individual, you must provide your Hong Kong Identity Card number or passport number. If you hold a Hong Kong Identity Card, please provide that number. If you do not hold a Hong Kong Identity Card, please provide your passport number. For a body corporate, please provide your Hong Kong Business Registration number.

如 閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請:如屬個別人士,必須填寫 閣下的香港身份證號碼或護照號碼(持有香港身份證者請填寫香港身份證號碼,否則請填寫護照號碼);如屬法人團體 請填寫香港商業登記號碼。

(3) Part of the Hong Kong Identity Card number/passport number of you or, for joint applicants, the first-named applicant may be printed on your refund cheque (if any). Such data will be used for checking the validity of Application Form and such data would also be transferred to a third party for such purpose and refund purpose. Your banker may require verification of your Hong Kong Identity Card number/passport number before you can cash your refund cheque.

退款支票(如有)或會印有 閣下或(如屬聯名申請人)排名首位申請人的香港身份證號碼/護照號碼的一部分。有關資料將用於核實申請表格的有效性,亦會轉交第三方作資料核實和退款。銀行兑現退款支票前或會要求查證 閣下的香港身份證號碼/護照號碼。

- (4) If an application is made by an unlisted company and:
  - the principal business of that company is dealing in securities; and
  - you exercise statutory control over that company, then the application will be treated as being made for your benefit.

倘若申請人是一家非上市公司,而:

- 該公司主要從事證券買賣業務;及
- 閣下對該公司可行使法定控制權,是項申請將視作為 閣下的利益提出。
- (5) All joint applicants must give (if they are individuals) their Hong Kong Identity Card numbers or, where applicable, passport numbers, or (if they are bodies corporate) their Hong Kong Business Registration numbers.

所有聯名申請人必須提供(如屬個別人士)其香港身份證號碼或(如適用)護照號碼,或(如屬法人團體)其香港商業登記號碼。

#### Mixed Media Offer

The Company will be relying on Section 9A of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong) and will be issuing (a) the WHITE and YELLOW Application Forms without them being accompanied by a printed Prospectus and (b) the BLUE Application Forms to the relevant Qualifying Fosun International Shareholders without them being accompanied by a printed Prospectus, unless the relevant Qualifying Fosun International Shareholders have elected to receive corporate communications in printed form under Fosun International's corporate communications policy or have not been asked to elect the means of receiving Fosun International's corporate communications, in which case the printed Prospectus will be despatched to them separately. The contents of the printed Prospectus are identical to the electronic version of the Prospectus which can be accessed and downloaded from the websites of the Company at www. sisram-medical.com and the Stock Exchange at www.hkexnews.hk under the "HKExnews > Listed Company Information > Latest Listed Company Information" section, respectively.


Members of the public and Qualifying Fosun International Shareholders may obtain a copy of the printed Prospectus, free of charge, upon request during normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017 at the following locations:

- 1. any of the following branches of the receiving banks for the Hong Kong Public Offering:
- (a) Standard Chartered Bank (Hong Kong) Limited

	Branch Name	Address
Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
Kowloon	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan

#### 混合媒介要約

本公司將依據香港法例第32L章《公司(豁免公司及招股章程遵從條文)公告》第9A條寄發(a)並未隨附招股章程印刷本的白色及黃色申請表格及(b)並未隨附招股章程印刷本並寄予相關合資格復星國際股東的藍色申請表格。除非相關合資格復星國際股東已選擇根據復星國際通訊政策收取公司通訊印刷本或未被要求選擇收取復星國際公司通訊稿的方式,在此情况下,招股章程印刷本會分開寄予被等。招股章程的印刷本的內容與招股章程的電子版本一致,可分別在本公司網站 www.siram-medical.com 及聯交所網站 www.hkexpews.hk中「披露易>上市公司公告>最新上市公司公告」可供查閱及下載。



- 1. 香港公開發售收款銀行的下列任何分行:
- (a) 渣打銀行(香港)有限公司

	分行名稱	
港島區	88 德輔道中分行	中環德輔道中88號
九龍區	旺角分行	旺角彌敦道617-623號地下B舖, 一樓及二樓
新界區	荃灣分行	荃灣沙咀道298號翡翠商場地下 C舖及一樓

- 2. any of the following offices of the Hong Kong Underwriters:
  - (a) China International Capital Corporation Hong Kong Securities Limited, at 29th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong; and
  - (b)Jefferies Hong Kong Limited, at Suite 2201, at 22/F, Cheung Kong Center, 2 Queen's Road Central, Central, Hong Kong; and
  - (c) Fosun Hani Securities Limited, at Suite 2101-2105, 21/F, Champion Tower, 3 Garden Road, Central, Hong Kong; and
  - (d)Haitong International Securities Company Limited, 22/F, Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong; and
  - (e) Huatai Financial Holdings (Hong Kong) Limited, Room 5801-05 & 08-12, 58/F, The Center, 99 Queen's Road Central, Hong Kong
- the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Details of where printed Prospectuses may be obtained will be displayed prominently at every designated branch of Standard Chartered Bank (Hong Kong) Limited where WHITE Application Forms are distributed.


During normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017, at least three copies of the printed Prospectus will be available for inspection at every location where the WHITE and YELLOW Application Forms are distributed as set out in "How to Apply for Hong Kong Offer Shares and Reserved Shares" in the Prospectus.

# 2. 香港包銷商的下列任何辦事處:

- (a) 中國國際金融香港證券有限公司,地址 為香港中環港景街1號國際金融中心第一 期29樓;及
- (b) 富瑞金融集團香港有限公司 地址為香港中環皇后大道中2號長江集團中心22樓 2201室,及
- (c) 復星恒利證券有限公司, 地址為香港中環花園道3號冠君大厦21樓2101-2105室; 及
- (d)海風國際證券有限公司,地址為香港德輔道中189號李寶椿大廈22樓;及
- (e) 華泰金融控股(香港)有限公司,地址為香港皇后大道中99號中環中心58樓5801至05室及08至12室
- 3 香港中環康樂廣場8號交易廣場一座及二座 1樓香港結算存管處服務櫃檯。

可索取招股章程印刷本的地址詳情將於派發**白**色申請表格的渣打銀行(香港)有限公司各指定分行以顯眼方式展示。

於二零一七年九月五日(星期二)上午九時正至 二零一七年九月八日(星期五)中午十二時正的 正常辦公時間內,在招股章程「如何申請香港 發售股份及預留股份」中所載派發**白色及黃色** 申請表格的各個地點,均有至少三份招股章程 印刷本可供查閱。



This page is intentionally left blank 此乃白頁 特意留空



## How to make your application

1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 400 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

Sisram Medical Ltd (Stock Code 1696)									
(HK\$12.35 per Hong Kong Offer Share)									
	NUMBER OF SHARES THAT MAY BE APPLIED FOR AND PAYMENTS								
No. of Hong Kong	Amount payable on	No. of Hong Kong	Amount payable on	No. of Hong Kong	Amount payable on	No. of Hong Kong	Amount payable on		
Offer Shares applied for	application HK\$	Offer Shares applied for	application HK\$	Offer Shares applied for	application	Offer Shares applied for	application H &\$		
400	4,989.78	8,000	99,795.61	70,000	873,211.57	900,000	11,227,005.86		
800	9,979.56	10,000	124,744.51	80,000	997,956.08	1,000,000	12,474,450.95		
1,200	14,969.34	12,000	149,693.41	90,000	1,122,700.59	1,500,000	18,711,676.43		
1,600	19,959.12	14,000	174,642.32	100,000	1,247,445.10	2,000,000	24,948,901.90		
2,000	24,948.91	16,000	199,591.22	200,000	2,494,890.19	2,500,000	31,186,127.38		
2,400	29,938.68	18,000	224,540.12	300,000	3,742,335.29	3,000,000	37,423,352.85		
2,800	34,928.46	20,000	249,489.02	400,000	4,989,780.38	3,500,000	43,660,578.33		
3,200	39,918.25	30,000	374,233.53	500,000	6,237,225.48	4,000,000	49,897,803.80		
3,600	44,908.02	40,000	498,978.04	600,000	7,484,670.57	4,500,000	56,135,029.28		
4,000	49,897.80	50,000	623,722.55	700,000	8,732,115.67	5,000,000	62,372,254.75		
6,000	74,846.71	60,000	748,467.06	800,000	9,979,560.76	5,500,000(1)	68,609,480.23		
						(1) Maximum number of Hong Kong Offer Shares you may apply for.			

- 2. You, as the applicant(s), must complete the form in English as indicated below and sign on the second page of the Application Form. Only written signatures will be accepted (and not by way of personal chop).
  - If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant):
  - the designated CCASS Participant must endorse the form with its company chop (bearing its company name) and insert its participant I.D. in the appropriate box.

If you are applying as an individual CCASS Investor Participant:

- the form must contain your NAME and Hong Kong I.D. Card number;
- your participant I.D. must be inserted in the appropriate box.

If you are applying as a joint individual CCASS Investor Participant:

- the form must contain all joint investor participants' NAMES and the Hong Kong I.D. Card number of all joint investor participants;
- your participant I.D. must be inserted in the appropriate box.

If you are applying as a corporate CCASS Investor Participant:

- the form must contain your company NAME and Hong Kong Business Registration number;
- your participant I.D. and your company chop (bearing your company name) must be inserted in the appropriate box.

Incorrect or omission of details of the CCASS Participant including participant I.D. and/or company chop bearing its company name or other similar matters may render your application invalid.

Staple your cheque or banker's cashier order to the form. Each application for the Hong Kong Offer Shares 3. must be accompanied by either one separate cheque or one separate banker's cashier order. Your application will be rejected if your cheque or banker's cashier order does not meet all the following requirements:

## The cheque must: Banker's cashier order must: be in Hong Kong dollars; not be post-dated; • be made payable to "HORSFORD NOMINEES LIMITED - SISRAM MEDICAL PUBLIC OFFER"; be crossed "Account Payee Only";

- be drawn on your Hong Kong dollar bank
- account in Hong Kong; and show your account name, which must either be preprinted on the cheque, or be endorsed on the back by a person authorised by the bank. This account name must correspond with your name. If it is a joint application, the account name must be the same as the first-named applicant's name.
- be issued by a licensed bank in Hong Kong, and have your name certified on the back by a person authorised by the bank. The name on the banker's cashier order must correspond with your name. If it is a joint application, the name on the back of the banker's cashier order must be the same as the first-named applicant's name.
- Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker's cashier order attached) to one of the collection boxes at any of the following branches of:

# Standard Chartered Bank (Hong Kong) Limited

	Branches	Address
Hong Kong Islands	88 Des Voeux Road Branch Hennessy Road Branch North Point Centre Branch	88 Des Voeux Road Central, Central 399 Hennessy Road, Wanchai Shop G, G/F, North Point Centre, 284 King's Road, North Point
Kowloon	Mongkok Branch Telford Gardens Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok Shop P9-12, Telford Centre, Telford Gardens, Tai Yip Street, Kwun Tong
New Territories	Tsuen Wan Branch Tseung Kwan O Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan Shop G37-40, G/F, Hau Tak Shopping Centre East Wing, Hau Tak Estate, Tseung Kwan O

Your Application Form can be lodged at these times:

```
Tuesday, September 5, 2017 — 9:00 a.m. to 5:00 p.m.
Wednesday, September 6, 2017 — 9:00 a.m. to 5:00 p.m.
 Thursday, September 7, 2017 — 9:00 a.m. to 5:00 p.m.
    Friday, September 8, 2017 — 9:00 a.m. to 12:00 noon
```

The latest time for lodging your application is by 12:00 noon on Friday, September 8, 2017. The application lists will be open between 11:45 a.m. and 12:00 noon on that day, subject only to the weather conditions, as described in "D. Effect of Bad Weather on the Opening and Closing of the Application Lists" in the "How to Apply for Hong Kong Offer Shares and Reserved Shares" section of the Prospectus.

# 申請手續

1. 使用下表計算 閣下應付的款項。 閣下申請認購的股數須至少為400股香港發售股份,並為下表所列的其中一個數目,否則不受理。

	Sisram Medical Ltd (股份代號 1696) (每股香港發售股份 12.35港元) 可供申請認購股份數目及應繳款項							
申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元	
400	4,989.78	8,000	99,795.61	70,000	873,211.57	900,000	11,227,005.86	
800	9,979.56	10,000	124,744.51	80,000	997,956.08	1,000,000	12,474,450.95	
1,200	14,969.34	12,000	149,693.41	90,000	1,122,700.59	1,500,000	18,711,676.43	
1,600	19,959.12	14,000	174,642.32	100,000	1,247,445.10	2,000,000	24,948,901.90	
2,000	24,948.91	16,000	199,591.22	200,000	2,494,890.19	2,500,000	31,186,127.38	
2,400	29,938.68	18,000	224,540.12	300,000	3,742,335.29	3,000,000	37,423,352.85	
2,800	34,928.46	20,000	249,489.02	400,000	4,989,780.38	3,500,000	43,660,578.33	
3,200	39,918.25	30,000	374,233.53	500,000	6,237,225.48	4,000,000	49,897,803.80	
3,600	44,908.02	40,000	498,978.04	600,000	7,484,670.57	4,500,000	56,135,029.28	
4,000	49,897.80	50,000	623,722.55	700,000	8,732,115.67	5,000,000	62,372,254.75	
6,000	74,846.71	60,000	748,467.06	800,000	9,979,560.76	5,500,000(1)	68,609,480.23	
					7	<sup>(1)</sup> 閣下可申請認購的香港 發售股份最高數目。		

- 2. 閣下作為申請人,必須按照下列指示以英文填妥表格,並於申請表格次頁簽署,只接納親筆簽 名(不得以個人印章代替)。
  - 如 閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請:
  - 該指定中央結算系統參與者必須於表格蓋上公司印鑑(附有公司名稱),並在適當方格內填寫 參與者編號。
  - 如 閣下以個人中央結算系統投資者戶口持有人名義提出申請:
  - 表格須載有 閣下的姓名和香港身份證號碼;
  - 須在適當方格內填寫 閣下的參與者編號。
  - 如 閣下以聯名個人中央結算系統投資者戶口持有人名義提出申請:
  - 表格須載有所有聯名投資者戶口持有人的姓名和香港身份證號碼;
  - 須在適當方格內填寫 閣下的參與者編號。
  - 如 閣下以公司中央結算系統投資者戶口持有人名義提出申請:
  - 表格須載有 閣下的公司名稱和香港商業登記號碼;
  - 須在適當方格內填寫 閣下的參與者編號並蓋上公司印鑑(附有公司名稱)。

中央結算系統參與者的資料(包括參與者編號及/或顯示公司名稱之公司印鑑)或其他類似事項如有不確或遺漏,均可能導致申請無效。

3. 閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出支票或一張獨立開出銀行本票。支票或銀行本票必須符合以下所有規定,否則有關的認購申請不獲接納:

## 支票必須:

# 銀行本票必須:

- 為港元;
- 不得為期票;
- 註明抬頭人為「浩豐代理人有限公司 SISRAM MEDICAL 公開發售」
- 劃線註明「只准入抬頭人賬戶」;
- 從 閣下在香港的港元銀行賬戶中開出;及
- 顯示 閣下的賬戶名稱,而該賬戶名稱必須 已預印在支票上,或由有關銀行授權的人士 在支票背書。賬戶名稱必須與 閣下姓名/ 名稱相同。如屬聯名申請,該賬戶名稱必須 與排名首位申請人的姓名/名稱相同。
- 須由香港持牌銀行開出,並由有關銀行授權的人士在銀行本票背面簽署核證 閣下姓名/名稱。銀行本票所示姓名/名稱必須與閣下姓名/名稱相同。如屬聯名申請,銀行本票背面所示姓名/名稱必須與排名首位申請人的姓名/名稱相同。
- 4. 請撕下申請表格,對摺一次,然後將填妥的申請表格(連同支票或銀行本票)投入下列任何一家 分行特設的收集箱:

# 渣打銀行(香港)有限公司

分行名稱

香港島 88 德輔道中分行

軒尼詩道分行

北角中心分行

德福花園分行

新界 荃灣分行 將軍澳分行

地址

中環德輔道中88號 灣仔軒尼詩道399號

北角英皇道284號北角中心地下G舖

旺角彌敦道617-623號地下B舖,一樓及二樓 觀塘大業街德福花園德福中心商場P9-12號舖

荃灣沙咀道298號翡翠商場地下C舖及一樓 將軍澳厚德邨厚德商場東翼地下G37-40號舖

- 5. 閣下可於下列時間遞交申請表格:
  - □零一七年九月五日(星期二) − 上午九時正至下午五時正
  - 二零一七年九月六日(星期三) 上午九時正至下午五時正
  - 二零一七年九月七日(星期四) 上午九時正至下午五時正
  - 二零一七年九月八日(星期五) 上午九時正至中午十二時正
- 6. 截止遞交申請的時間為二零一七年九月八日(星期五)中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間登記認購申請,唯一會影響此時間的變化因素為當日的天氣情況(詳見招股章程「如何申請香港發售股份及預留股份」一節「D.惡劣天氣對開始及截止辦理申請登記的影響」)。

## Sisram Medical Ltd

(Incorporated in Israel with limited liability)

#### GLOBAL OFFERING

#### **Conditions of your application**

#### A. Who can apply

- You and any person(s) for whose benefit you are applying must be 18 years of age or older and must have a Hong Kong address.
- 2. If you are a firm, the application must be in the individual members' names.
- 3. The number of joint applicants may not exceed 4.
- 4. If you are a body corporate, the application must be signed by a duly authorised officer, who must state his representative capacity, and stamped with your corporation's chop.
- 5. You must be outside the United States, not be a United States Person (as defined in Regulation S under the U.S. Securities Act) and not be a legal or natural person of the PRC.
- 6. Unless permitted by the Listing Rules, you cannot apply for any Hong Kong Offer Shares if you are:
  - an existing beneficial owner of shares in the Company and/or any of its subsidiaries;
  - a Director or chief executive officer of the Company and/or any of its subsidiaries;
  - a connected person of the Company or will become a connected person of the Company immediately upon completion of the Global Offering;
  - are a close associate (as defined in the Listing Rules) of any of the above;
  - have been allocated or have applied for or indicated an interest in any Offer Shares under the International Offering (except in respect of Reserved Shares applied for pursuant to the Preferential Offering).

#### B. If you are a nominee

You, as a nominee, may make more than one application for the Hong Kong Offer Shares by: (i) giving electronic instructions to HKSCC via Central Clearing and Settlement System ("CCASS") (if you are a CCASS Participant); or (ii) using a WHITE or YELLOW Application Form, and lodge more than one application in your own name on behalf of different beneficial owners.

- C. Effect of completing and submitting this Application Form
  By completing and submitting this Application Form, you (and
  if you are joint applicants, each of you jointly and severally) for
  yourself or as an agent or a nominee on behalf of each person
  for whom you act:
  - undertake to execute all relevant documents and instruct and authorise the Company and/or the Joint Global Coordinators (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Hong Kong Offer Shares allocated to you in the name of HKSCC Nominees as required by the Articles of Association:
  - agree to comply with the Israeli Companies Law, the Companies Ordinance, the Companies (Winding Up and Miscellaneous Provisions) Ordinance, the Memorandum of Association and the Articles of Association
  - confirm that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;
  - confirm that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in

- making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;
- confirm that you are aware of the restrictions on the Global Offering in the Prospectus;
- agree that none of the Company, the Joint Global Coordinators, the Underwriters, their respective directors, officers, employees, partners, agents, advisers and any other parties involved in the Global Officing is or will be liable for any information and representations not in the Prospectus (and any supplement to it);
- undertake and confirm that you or the person(s) for whose benefit you have made the application have not applied for or taken up, or indicated interest for, and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor participated in the International Offering (except in respect of Reserved Shares applied for pursuant to the Preferential Offering);
- agree to disclose to the Company, our Hong Kong Share Registrar, receiving bank the Joint Global Coordinators, the Underwriters and/or their respective advisers and agents any personal data which they may require about you and the person(s) for whose benefit you have made the application;
- if the laws of any place outside Hong Kong apply to your application, agree and warrant that you have complied with all such laws and none of the Company, the Joint Global Coordinators and the Underwriters nor any of their respective officers or advisers will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in the Prospectus and this Application Form;
- agree that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- agree that your application will be governed by the laws of Hong Kong;
- represent, warrant and undertake that (i) you understand that the Hong Kong Offer Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Hong Kong Offer Shares are outside the United States (as defined in Regulation S) or are a person described in paragraph (h)(3) of Rule 902 of Regulation S;
- warrant that the information you have provided is true and
- agree to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to you under the application:
- authorize the Company to place your name(s) or the name of the HKSCC Nominees on the Company's register of members as the holder(s) of any Hong Kong Offer Shares allocated to you, and the Company and/or its agents to send any Share certificate(s) and/or any e-Refund payment instructions and/or any refund cheque(s) to you or the first—named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you are eligible to collect the Share certificate(s) and/or refund cheque(s) in person;
- agree that the shares to be allotted shall be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your investor participant stock account or the stock account of your designated CCASS Participant;

- agree that each of HKSCC and HKSCC Nominees reserves the right (1) not to accept any or part of such allotted shares issued in the name of HKSCC Nominees or not to accept such allotted shares for deposit into CCASS; (2) to cause such allotted shares to be withdrawn from CCASS and issued in your name at your own risk and costs; and (3) to cause such allotted shares to be issued in your name (or, if you area joint applicant, to the first-named applicant) and in such a case, to post the certificates for such allotted shares at your own risk to the address on your application form by ordinary post or to make available the same for your collection;
- agree that each of HKSCC and HKSCC Nominees may adjust the number of allotted shares issued in the name of HKSCC Nominees;
- agree that neither HKSCC nor HKSCC Nominees shall have any liability for the information and representations not so contained in the Prospectus and this application form:
- agree that neither HKSCC nor HKSCC Nominees shall be liable to you in any way;
- declare and represent that except for an application made by a Qualifying Fosun International Shareholder under the Preferential Offering, this is the only application made and the only application intended by me/us to be made to benefit me/us or the person for whose benefit I am/we are applying;
- understand that the Company and the Joint Global Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Hong Kong Offer Shares to you and that you may be prosecuted for making a false declaration:
- (if the application is made for your own benefit) warrant that no other application has been or will be made for your benefit on a WHITE or YELLOW Application Form or by giving electronic application instructions to HKSCC or to the White Form eIPO Service Provider by you or by any one as your agent or by any other person (except in respect of application for Reserved Shares pursuant to the Preferential Offering); and
- (if you are making the application as an agent for the benefit of another person) warrant that (i) no other application has been or will be made by you as agent for or for the benefit of that person or by that person or by any other person as agent for that person on a WHITE or YELLOW Application Form or by giving electronic application instructions to HKSCC (except in respect of application for Reserved Shares pursuant to the Preferential Offering); and (ii) you have due authority to sign the Application Form or give electronic application instructions on behalf of that other person as their agent.

#### D. Power of attorney

If your application is made through an authorised attorney, the Company and the Joint Global Coordinators may accept or reject your application at their discretion, and on any conditions they think fit, including evidence of the attorney's authority.

# **Determination of Offer Price and Allocation of Hong Kong Offer Shares**

The Offer Price is expected to be fixed on or around Monday, September 11, 2017. Applicants are required to pay the maximum Offer Price of HK\$12.35 for each Hong Kong Offer Share together with 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee. If the Offer Price is not agreed between the Company, and the Joint Global Coordinators (on behalf of the underwriters) on or before Monday, September 18, 2017, the Global Offering will not proceed.

Applications for Hong Kong Offer Shares will not be processed and no allotment of any Hong Kong Offer Shares will be made until the application lists close.

The Company expects to announce the fixed offer price, the indication of the level of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the Preferential Offering and the basis of allocation of the Long Kong Offer Shares and Reserved Shares on Monday, September 18, 2017 in South China Morning Post (in English) and Hong Kong Economic Times (in Chinese), the website of the Stock Exchange a www.h.exnews.hk and the Company's website at www.sisran-medical.com. Results of allocations, and the Hong Kong Identity Card/passport/Hong Kong business registration numbers of successful applicants (where applicable) will be available on the above websites.

# If your application for Hong Kong Offer Shares is successful (in whole or in part)

If your application is wholly or partially successful, your Share certificate(s) (subject to their becoming valid certificates of title provided that the Hong Kong Public Offering has become unconditional and not having been terminated at 8:00 a.m. on Tuesday, September 19, 2017) will be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant as instructed by you in your Application Form on Tuesday September 19, 2017 or, in the event of a contingency, on any other date as shall be determined by HKSCC or HKSCC Nominees.

- If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For Hong Kong Offer Shares credited to the stock account of your designated CCASS Participant (other than a CCASS Investor Participant), you can check the number of Hong Kong Offer Shares allotted to you with that CCASS Participant.
- If you are applying as a CCASS Investor Participant: The Company expects to publish the results of CCASS Investor Participants' applications together with the results of the Hong Kong Public Offering in South China Morning Post (in English) and Hong Kong Economic Times (in Chinese) on Monday, September 18, 2017. You should check the announcement published by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Monday, September 18, 2017 or such other date as shall be determined by HKSCC or HKSCC Nominees. Immediately after the credit of the Hong Kong Offer Shares to your stock account you can check your new account balance via the CCASS Phone System and CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). HKSCC will also make available to you an activity statement showing the number of Hong Kong Offer Shares credited to your stock account.

No receipt will be issued for application money paid. The Company will not issue temporary documents of title.

#### Refund of your money

If you do not receive any Hong Kong Offer Shares or if your application is accepted only in part, the Company will refund to you your application monies (including the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee) without interest. If the Offer Price is less than the Maximum Offer Price, the Company will refund to you the surplus application monies (including the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee) without interest.

The refund procedures are stated in the "H. Despatch/Collection of Share Certificates and Refund Monies" in the "How to Apply for Hong Kong Offer Shares and Reserved Shares" section of the Prospectus.

# **Sisram Medical Ltd**

(於以色列註冊成立的有限公司)

# 全球發售

#### 申請條件

# 甲. 可提出申請的人士

- 閣下及 閣下為其利益提出申請的人士必須年滿 18歲並有香港地址。
- 2. 如 閣下為商號,申請須以個別成員名義提出。
- 3. 聯名申請人不得超過四名。
- 如 閣下為法人團體,申請須經獲正式授權人員 簽署,並註明其所屬代表身份及蓋上公司印鑑。
- 5. 閣下必須身處美國境外,並非美國籍人士(定義 見美國《證券法》S規例),亦非中國法人或自然 人。
- 除《上市規則》批准外,下列人士概不得申請認購 任何香港發售股份:
  - 本公司及/或其任何附屬公司股份的現有 實益擁有人;
  - 本公司及/或其任何附屬公司的董事或最高行政人員;
  - 本公司關連人士或緊隨全球發售完成後成 為本公司關連人士的人士;
  - 上述任何人士的聯繫人(定義見上市規則):
  - 已獲分配或已申請或表示有意申請國際發售的任何發售股份(有關根據優先發售的預留股份除外)。

## 乙. 如 閣下為代名人

閣下作為代名人可提交超過一份香港發售股份申請, 方法是:(i)透過中央結算及交收系統(中央結算系統」)向香港結算發出電子認購指示(如 閣下為中央 結算系統參與者);或(ii)使用白色或黃色申請表格以 自身名義代表不同的實益擁有人提交超過一份申請。

#### 丙. 填交本申請表格的效用

閣下填妥並遞交本申請表格,即表示 閣下(如屬聯名申請人,即各人共同及個別)代表 閣下本身,或 作為 閣下代其行事的每位人士的代理或代名人:

- 承諾促使所有相關文件生效,並指示及授權本公司及一或作為本公司代理的聯席全球協調人(或被等的代理或代名人),代表 閣下促使任何文件生效,並為按照組織章程細則的規定將 閣下獲分配的任何香港發售股份以香港結算代理人的名義登記;
- 同意遵守以色列公司法、《公司條例》、《公司(清 盤及雜項條文)條例》、組織章程大綱及組織章程 細則;
- 確認 閣下已細閱招股章程及本申請表格所載的 條款及條件以及申請程序,並同意受其約束;
- 確認 閣下已接獲及細閱招股章程,提出申請時 也僅依據招股章程載列的資料及陳述,而除招股 章程任何補充文件外,不會依賴任何其他資料或 陳述;

- 確認 閣下知悉招股章程內有關全球發售的限制;
- 同意本公司、聯席全球協調人、包銷商、彼等各自的董事、高級職員、僱員、合夥人、代理、顧問及參與全球發售的任何其他人士現時及日後均毋須對並非載於招股章程(及其任何補充文件)的任何資料及陳述負責;
- 承諾及確認 閣下或 閣下為其利益提出申請的 人士並無申請或接納或表示有意認購(亦不會申 請或接納或表示有意認購)國際發售的任何發售 股份,也沒有參與國際發售(有關根據優先發售 的預留股份除外);
- 同意在本公司、香港證券登記處、收款銀行、聯席全球協調人、包銷商及/或彼等各自的顧問及代理提出要求時,向彼等披露其所要求提供有關。
   關下及。關下為其利益提出申請的人士的個人資料;
- 若香港境外任何地方的法例適用於 閣下的申請,則同意及保證 閣下已遵守所有有關法例, 且本公司、聯席全球協調人及包銷商和彼等各自 的高級職員或顧問概不會因接納 閣下的購買要 約,或 閣下在招股章程及本申請表格所載的條 款及條件項下的權利及責任所引致的任何行動, 而違反香港境外的任何法例;
- **同意** 閣下的申請一經接納,即不得因無意的失 實陳述而撤銷;
- 同意 閣下的申請受香港法例規管;
- 聲明、保證及承諾:(i) 閣下明白香港發售股份 不曾亦不會根據美國《證券法》登記;及(ii)閣下 及 閣下為其利益申請香港發售股份的人士均身 處美國境外(定義見S規例),或屬S規例第902 條第(h)(3)段所述的人士;
- 保證 閣下提供的資料真實及準確;
- **同意**接納所申請數目或根據申請分配予 閣下但 數目較少的香港發售股份;
- 授權本公司將 閣下的姓名或香港結算代理人的名稱列入本公司股東名冊,作為 閣下獲分配的任何香港發售股份的持有人,並授權本公司及/或其代理以普通郵遞方式按申請所示地址向 閣下或聯名申請的首名申請人發送任何股票及/或任何電子退款指示及/或任何退款支票,郵誤風險由 閣下承擔,除非 閣下已符合資格親身領取股票及/或退款支票;
- 同意獲配發的股份是以香港結算代理人的名義發行,並直接存入中央結算系統,以便記存於 閣下的中央結算系統投資者戶口持有人股份戶口或 閣下的指定中央結算系統參與者股份戶口;

- 同意香港結算及香港結算代理人各自保留權利 (1)不接納以香港結算代理人名義發行的該等獲 配發的任何或部分股份,或不接納該等獲配發 的股份存入中央結算系統;(2)促使該等獲配發 的股份從中央結算系統提取,並轉入 閣下名 下,有關風險及費用概由 閣下自行承擔;及 (3)促使該等獲配發的股份以 閣下名義發行(或 如屬聯名申請人,則以排名首位申請人的名義發 行),而在此情況下,會以普通郵遞方式將該等 獲配發股份的股票寄往 閣下在申請表格上所示 地址(郵誤風險概由 閣下自行承擔)或提供該等 股票予 閣下領取;
- 同意香港結算及香港結算代理人均可調整獲配發 以香港結算代理人名義發行的股份數目;
- 同意香港結算及香港結算代理人對招股章程及本申請表格未有載列的資料及陳述概不負責;
- 同意香港結算及香港結算代理人概不以任何方式 對 閣下負責;
- 聲明及表示(合資格復星國際股東根據優先發售 作出申請除外)此乃本人/吾等為本身或本人/ 吾等為其利益提出申請的人士提出及擬提出的唯 一申請;
- 明白本公司及聯席全球協調人將依據 閣下的聲明及陳述而決定是否向 閣下分配任何香港發售股份,閣下如作出虛假聲明,可能會被檢控;
- (如本申請是為 閣下本身利益提出)保證 閣下 或作為 閣下代理的任何人士或任何其他人士不 曾亦不會為 閣下利益而以白色或黃色申請表格 或向香港結算或白表eIPO服務供應商發出電子 認購指示而提出其他申請(有關根據優先發售申 請預留股份除外);及
- (如 閣下作為代理為另一人士的利益提出申請)保證(i) 閣下(作為代理或為該人士利益)或該人士或任何其他作為該人士代理的人士不曾亦不會以白色或黃色申請表格或向香港結算發出電子認購指示而提出其他申請(有關根據優先簽售申請預留股份除外);及(ii) 閣下獲正式授權作為該人士的代理代為簽署本表格或發出電子認購指示。

# 丁. 授權書

如 閣下透過授權人士提出申請,本公司及聯席全球協調人可投其認為合適的條件(包括出示獲授權證明) 酌情接納或拒絕 閣下的申請。

### 釐定發售價及香港發售股份的分配

預期發售價於二零一七年九月十一日(星期一)或前後釐定。申請人須繳付每股香港發售股份12.35港元的最高發售價,另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。倘若本公司與聯席全球協調人(代表包銷商)並無於二零一七年九月十八日(星期一)或之前協定發售價,全球發售將不會進行。

截止登記認購申請前概不處理香港發售股份的申請或配發 任何香港發售股份。

本公司預期於二零一七年九月十八日(星期一)在南華早報(英文)、香港經濟日報(中文)、聯交所網站(www.hkexnews.hk)及本公司網站www.sisram-medical.com公布協定發售價、國際發售踴躍程度、香港公開發售及優先發售認購水平及香港發售股份及預留股份分配基準。分配結果以及成功申請人的香港身份證/護照/香港商業登記號碼(如適用)亦同於上述網站公布

## 如 閣下成功申請認購香港發售股份(全部或部分)

如 閣下的申請全部或部分獲接納,閣下的股票(前提是到二零一七年九月十九日(星期二)上午八時正香港公開發售成為無條件而並無終止,股票成為有效的所有權證明)將以香港結算代理人名義發出;並按 閣下在申請表格的指示於二零一七年九月十九日(星期二)或在特別情況下由香港結算或香港結算代理人指定的任何其他日期直接存入中央結算系統,記入 閣下的中央結算系統參與者股份戶口。 閣下指定的中央結算系統參與者股份戶口。

- 如 閣下透過中央結算系統投資者戶口持有人以外的 指定中央結算系統參與者提出申請:香港發售股份將 存入 閣下指定的中央結算系統參與者(非中央結算 系統投資者戶口持有人)股份戶口, 閣下可向該中央 結算系統參與者查詢 閣下獲配發的香港發售股份數 日。
  - 如 閣下以中央結算系統投資者戶口持有人身份提出 申請:本公司預期於二零一七年九月十八日(星期一) 在南華早報(英文)及香港經濟日報(中文)刊登中央結 算系統投資者戶口持有人的申請結果及香港公開發售 的結果。 閣下應查閱本公司刊發的公告,如有任何 資料不符,請於二零一七年九月十八日(星期一)下午 五時正前或香港結算或香港結算代理人釐定的任何其 他日期前知會香港結算。在香港發售股份存入 閣下 的股份戶口後, 閣下即可透過「結算通」電話系統及 中央結算系統互聯網系統(根據香港結算當時生效的 《投資者戶口操作簡介》所載程序)查詢 閣下的新戶 口結餘。香港結算亦將向 閣下提供一份活動結單, 列出存入 閣下股份戶口的香港發售股份數目。

本公司不會就申請時繳付的款項發出收據,亦不會發出臨時所有權文件。

#### 退回款項

若 閣下未獲分配任何香港發售股份或申請僅部分獲接納,本公司將不計利息退回 閣下的申請股款(包括相關的1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)。如最終釐定的發售價低於最高發售價,本公司將不計利息退回多收申請股款(包括相關的1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)。

有關退款程序載於招股章程「如何申請香港發售股份及預留 股份」一節「H. 發送/領取股票及退回股款」一段。

#### **Personal Data**

### **Personal Information Collection Statement**

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance").

## 1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

#### 2. Purposes

The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities' holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities' holders of the Company;
- verifying securities holders' identities;
- establishing benefit entitlements of securities' holders of the Company, such as dividends, rights issues, bonus issues, etc.:
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities' holders profiles;
- disclosing relevant information to facilitate claims on entitlements; and

 any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities' holders and/or regulators and/or any other purposes to which the securities' holders may from time to time agree.

## 3. Transfer of personal data

Personal data held by the Company and its Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company's appointed agents such as financial advisers, receiving bankers and overseas principal share registrar;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities' holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

## 4. Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

#### 5. Access to and correction of personal data

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the "Corporate Information" section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

## 個人資料

## 個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請 人和持有人説明有關本公司及其香港證券登記處 有關個人資料和香港法例第486章《個人資料(私 隱)條例》(「《條例》」)方面的政策和慣例。

# 1. 收集 閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或 轉讓或受讓證券時或尋求香港證券登記處的服務 時,必須向本公司或其代理人及香港證券登記處 提供準確個人資料。

未能提供所要求的資料可能導致 閣下申請證券被拒或延遲,或本公司或其香港證券登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓 閣下成功申請的香港發售股份及/或寄發 閣下應得的股票及/或退款支票。

證券持有人所提供的個人資料如有任何錯誤,須立即通知本公司及香港證券登記處。

## 2. 目的

證券持有人的個人資料可被採用及以任何方式持有,處理及/或保存,以作下列用途:

- 處理 閣下的申請及退款支票(如適用)、核 實是否符合本申請表格及招股章程載列的條 款和申請程序以及公布香港發售股份的分配 結果;
- 遵守香港及其他地區的適用法律及法規;
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券;
- 存置或更新本公司證券持有人的名冊;
- 核實證券持有人的身份;
- 確定本公司證券持有人的受益權利,例如股息、供股和紅股等;
- 分發本公司及其附屬公司的通訊;
- 編製統計數據和證券持有人資料;
- 披露有關資料以便就權益索償;及

與上述有關的任何其他附帶或相關目的及/ 或使本公司及香港證券登記處能履行對證券 持有人及/或監管機構承擔的責任及/或證 券持有人不時同意的任何其他目的。

# 3. 轉交個人資料

本公司及其香港證券登記處所持有關證券持有人 的個人資料將會保密,但本公司及其香港證券登 記處可以在為達到上述任何目的之必要情况下, 向下列任何人士披露,獲取或轉交(無論在香港 境內或境外)有關個人資料:

- 本公司委任的代理人,例如財務顧問、收款 銀行和主要海外股份過戶登記處;
- (如證券申請人要求將證券存於中央結算系統)香港結算或香港結算代理人;彼等將會就中央結算系統的運作使用有關個人資料;
- 向本公司或香港證券登記處提供與其各自業務管運有關的行政、電訊、電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商;
- 聯交所、證監會及任何其他法定監管機關或 政府部門或遵照其他法例、規則或法規;及
- 證券持有人與其進行或擬進行交易的任何人 士或機構,例如彼等的銀行、律師、會計師 或股票經紀等。

## 4. 個人資料的保留

本公司及其香港證券登記處將按收集個人資料所 需的用途保留證券申請人及持有人的個人資料。 無需保留的個人資料將會根據條例銷毀或處理。

# 5. 查閱和更正個人資料

證券持有人有權確定本公司或香港證券登記處是 否持有其個人資料,並有權索取有關該資料的副本並更正任何不準確資料。本公司和香港證券登 記處有權就處理任何查閱資料的要求收取合理費用。

所有查閱資料或更正資料的要求應按招股章程 「公司資料」一節所披露或不時通知的本公司註冊 地址送交公司秘書,或向本公司的香港證券登記 處的個人資料私隱事務主任提出。

閣下簽署申請表格或向香港結算發出電子認購指 示,即表示同意上述各項。